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Abstract
Fabry disease is a rare X-linked lysosomal storage disorder in which there is deficiency of alpha 
galactosidase A. Enzyme replacement therapy (ERT) is commercially available and has been 
demonstrated to improve cardiac and renal outcomes. Predictive scores, such as the Fabry 
International Prognostic Index (FIPI), have been developed to stratify disease severity; 
however, these have not been validated to predict outcomes in patients receiving ERT.  We 
show that the FIPI score at baseline can predict outcomes in a group of patients on long-term 
ERT.  
Keywords: Fabry disease; alpha galactosidase A; Enzyme replacement therapy; Agalsidase 
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1. Introduction
Fabry disease is a rare X-linked lysosomal storage disorder in which deficiency of the 
enzyme alpha galactosidase A results in cellular accumulation of globotriaosylceramide. The 
manifestations of the disease are multiple and diverse, and include chronic pain, 
gastrointestinal symptoms, a characteristic rash (angiokeratoma), cardiomyopathy and 
cardiac conduction defects, renal failure, stroke and transient ischaemic attacks (TIAs). 
Replacement of alpha galactosidase A by intravenous infusion gained marketing approval in 
the EU in 2001, and is currently commercially available in two formulations: agalsidase alpha 
(Replagal, Shire Pharmaceuticals) and agalsidase beta (Fabrazyme, Genzyme Corp.)  
The clinical manifestations of the condition are heterogeneous and not accurately predicted 
by genotype alone. Clinical scores have been developed to quantify disease severity e.g. 
Mainz Severity Score Index (MSSI) (Whybra et al., 2004) and attempts have been made to 
develop predictive scores to stratify disease severity, e.g. the Fabry International Prognostic 
Index (FIPI) (Hughes et al., 2012). The FIPI was developed using clinical and pathological data 
from 1483 patients in the Fabry Outcome Survey (FOS), an international registry of Fabry 
disease patients. We used a univariate analysis to identify and select candidate prognostic 
factors which correlated with clinically-relevant outcomes; these were further refined using 
a multivariate analysis and assigned a weighted score corresponding with their level of 
statistical significance (Hughes et al., 2012). The overall score utilizes information from clinical 
history, examination, and routine investigations to predict disease-related outcomes in five 
domains: serious cardiac events, renal events, neurological events, and all-cause mortality, 
and a ‘composite’ endpoint representing any of the above. To date, the use of the FIPI and 
associated organ system scores in predicting response to ERT has not been explored.
This study analyses the 15 patients that participated in an initial clinical trial of 
agalsidase alpha (Replagal, Shire Pharmaceuticals) (Hughes et al., 2008). Participants 
underwent double-blind randomized allocation to either agalsidase alpha (0.2mg/kg by 
intravenous infusion every two weeks) or placebo for 6 months. Subsequently, the patients 
were then enrolled in an open-label follow up during which they received agalsidase alpha 
(0.2mg/kg every two weeks) for a further two years. This cohort of patients has been receiving 
enzyme replacement therapy and continually followed up for over 16 years, longer than any 
published to date.
2. Materials and Methods
2.1 Patients
All 15 patients were male hemizygotes with a confirmed diagnosis of Fabry disease by both 
genotyping and leukocyte alpha galactosidase A activity. Detailed demographics have already 
been published (Hughes et al., 2008).  In terms of mutations, 7 patients had a missense 
mutation in GLA, 5 patients had a nonsense mutation in GLA, and the remaining 3 patients 
had deletion mutations resulting in frameshifts.  This study reviewed patients involved in the 
original clinical trial and was not funded by a commercial sponsor. All patents received the 
best current standard of care funded through the NHS.
2.2 Clinical outcomes
A retrospective case note review was conducted in March 2014 for all 15 patients who 
participated in the original trial (Hughes et al., 2008). Significant outcomes were categorized 
into cardiac, renal, neurological, and all-cause mortality.  Cardiac endpoints were defined as 
myocardial infarction, cardiac surgery, major valvular disease, pacemaker or ICD insertion, or 
reaching New York Heart Association grade III or IV status. Renal endpoints were defined as 
end-stage renal failure requiring dialysis or renal transplant. Neurological endpoints were 
defined as stroke, TIA, or prolonged reversible ischaemic neurological event (PRIND).  A 
‘composite’ endpoint was defined as any cardiac, renal, or neurological event as previously 
defined, or mortality.
2.3 Neutralising antibodies
During the double-blinded, placebo-controlled phase of the initial trial, participants were 
tested for serum anti-Replagal antibodies at baseline, 9 weeks post initiation, 17 weeks post 
initiation and 24 weeks post initiation. This was continued during the two-year open label 
extension, with measurements taken at 13, 27, 41, 55, 81 and 107 weeks post initiation of 
ERT.  Specimens were assessed for in-vitro neutralising activity and defined as containing a 
positive neutralising antibody where percentage of neutralizing activity was greater than 50%. 
For the purposes of this paper, patients who developed a positive neutralising antibody at 
any time during these measurement periods were defined as having a positive antibody 
status.
2.4 Urinary and plasma Gb3
Urinary and plasma Gb3 levels were calculated at baseline (pre-treatment) as described in 
Hughes et al., 2008.
2.5 Risk stratification
Participants were risk-scored using two scoring systems, the Mainz Severity Score 
Index (MSSI) and the Fabry International Prognostic Index (FIPI). This was retrospectively 
calculated for the point of initiation of enzyme replacement therapy using case records from 
the initial trial.
The MSSI uses information from history, examination, serum creatinine, 
electrocardiography, echocardiography, urinalysis, and magnetic resonance and computed 
tomography scans of the brain to stratify patients into three groups of overall disease 
severity: mild, moderate, and severe (Whybra et al., 2004).
The FIPI uses history, examination, electrocardiography, serum creatinine, urinalysis, 
pure tone audiometry and echocardiography to calculate risk scores in four domains: cardiac, 
renal, neurological and a composite score based on outcomes in any of those categories, plus 
all-cause mortality (Hughes et al. 2012). 
Cardiac, renal, and neurological scores may be stratified into three groups according 
into risk of developing organ-related serious adverse outcomes depending on the calculated 
score:  low (0-2), medium (3-4), and high- (5-7). Composite or FIPI scores are stratified into 
two groups according to risk of reaching any organ-specific adverse outcome or mortality: low 
(0-3) and high (4-7).
2.6 Statistical Analyses
Kaplan-Meier analysis was performed to assess the ability of the MSSI score, the FIPI 
scoring system, patient genotypes, antibody status, and urinary and plasma GL3 
concentration to predict between-group differences in time to cardiac, renal, neurological, or 
composite endpoints. 
All data were analysed with an intention-to-treat principle.  Statistical analysis and 
graphing were performed using IBM SPSS version 20 for Windows, IBM Corp., Armonk, New 
York, USA, and GraphPad Prism version 6.00 for Windows, GraphPad Software, La Jolla 
California USA.
3. Results 
3.1 Patient treatment history on ERT  
In general, ERT was well-tolerated by this group of patients, and there were no recorded 
adverse effects on clinical note review. Eleven of the fifteen patients received uninterrupted 
ERT during the follow-up period.  One patient entered a Phase II trial of investigational 
therapy seven years after initiating ERT and up to the end of the follow-up period. Another 
patient entered a trial twelve years after initiating ERT, and returned to ERT monotherapy for 
the rest of the follow-up period.  After two years of agalsidase alfa therapy, one patient 
switched from agalsidase alfa to agalsidase beta due to deteriorating renal function on the 
former;  four years after initiation of ERT, the same patient experienced a four-month 
interruption in ERT due to issues with funding. This was subsequently resolved, and the 
patient received uninterrupted therapy with agalsidase beta for the rest of the follow-up 
period.  Another patient experienced brief intermittent interruptions in enzyme replacement 
therapy due to non-compliance. 
3.2 Risk stratification 
Using the FIPI composite scoring system at baseline prior to ERT initiation, 6/15 patients were 
classified as low-risk overall and 9/15 patients as high risk overall. At the time of risk score 
calculation, mean age in the low-risk group was 31.3 (range 23-43) and mean age in the high-
risk group was 41.9 (range 34-51). This difference was statistically significant using an 
unpaired T test (p=0.014).  Comparison of composite FIPI scores and mutation type is shown 
in Table 1.
3.3 Urinary and plasma Gb3 concentrations
The median urinary sediment Gb3 concentration at baseline (prior to ERT therapy) was 
1725nmol/24hr (range 35 to 4559nmol/24hr).  The median plasma Gb3 concentration at 
baseline was 14.14nmol/ml (range 3.36 to 18.35nmol/ml).
3.4 Significant outcomes  
Patient outcomes together with demographic and clinical information are summarized in 
Table 1. Three deaths occurred in the patient group, which were at 1.0, 10.3 and 13.4 years 
post-initiation of ERT and were attributable to perioperative complications of renal transplant 
surgery, a fatal ischaemic stroke, and a fatal myocardial infarction, respectively. Of the 
surviving patients, the mean length of follow up was 12.9 years from initiation of ERT (range: 
8.6-14.3 years) and the current median patient age at follow-up was 52 years (range: 37-65 
years).  
Seven patients experienced a serious disease-related cardiac event, which included two 
myocardial infarctions (one of which was fatal), two cases of severe mitral regurgitation, one 
insertion of a permanent cardiac pacemaker, one insertion of an implantable cardiac 
defibrillator, and one cardiac bypass operation for ischaemic heart disease. Within the FIPI 
cardiac subgroups, 1/2 of the “low-risk” FIPI cardiac patients experienced a cardiac event, 2/5 
of the “medium-risk” FIPI patients did so, and 4/7 of the “high-risk” FIPI patients experienced 
a cardiac event. 
Four patients developed a serious disease-related renal event:  in all cases this was the 
development of end-stage renal failure. 3/4 patients then received a renal allograft. All of the 
affected patients scored as “high-risk” on the FIPI renal prognostic score.
Five patients developed a serious disease-related neurological event. Three patients suffered 
a stroke (one patient died as a result), one patient had a transient ischaemic attack (TIA), and 
one had a TIA followed two years later by a stroke. Within the neurological score groups, 1/7 
of the ‘“low-risk” patients experienced a neurological event, 4/6 of the “medium-risk” 
patients experienced a neurological event, and 0/2 of the ”high-risk” group did so.
Four patients survived without experiencing any cardiac, renal or neurological serious adverse 
events during the 14 year follow-up period; all of these were rated as "low risk” using the FIPI 
composite scoring system.  
3.5 Endpoint prediction
 Kaplan-Meier analyses of the time to serious cardiac, renal or neurological events 
stratified by the corresponding organ-system predictive score are shown in Figures 1(a), 1(b), 
and 1(c), respectively; a breakdown of patients numbers in each risk group is shown in Table 
2. Comparisons using the log-rank test showed a significant difference was observed between 
high and low-risk FIPI groups in time to the composite end-point (p=0.029 (Figure 1d). There 
was no significant difference between the three risk groups for any of these scores (p=0.78 
for cardiac score; p=0.36 for renal score; and p=0.22 for neurological score).  
No significant difference in time to the composite end-point was observed between 
MSSI groups (p=0.19), different types of mutations (p=0.90), baseline urinary Gb3 
concentrations above or below the median value (p=0.63), plasma Gb3 levels above or below 
the median value (p=0.21) (data not shown), or patients with or without neutralising 
antibodies (p=0.99) (data not shown).
Table 1.  Individual patient details on mutation, risk stratification, and clinical outcomes 
grouped by organ system. (*temporarily related events)
Age  of 
start on 
ERT
Mutation MSSI Cardiacrisk group Cardiac events
Renal
risk 
group
Renal events Neuro.  risk group
Neurological 
events  FIPI group Other events
23 N215S  missense Mild Low - Low - Mild - Low -
25 717del2 Mild Medium - High - Mild - Low -
27 A143T missense Moderate Medium
Fatal myocardial 
infarction (40) High - Mild - Low -
30 R301X  nonsense Moderate Medium - Medium - Mild - Low
Bipolar disorder (38 
onwards)
40 R49L  missense Severe Medium - Medium - Mild - Low -
43 R227X  (nonsense) Moderate Medium - Medium - Mild Fatal stroke (53) Low
Chronic severe 
depression (48), 
suicide attempt (49)
34 R227X nonsense Severe High - High
Dialysis-dependent 
renal failure (37), 
renal transplant (38)
Moderate TIA (39) High
Switched from 
Replagal to 
Fabrazyme in 2002
36 W209X nonsense Moderate High
Non-ST elevation 
myocardial 
infarction (49)
High - Severe - High -
37 520delT Moderate High - High End stage renal failure (49) Moderate - High -
38 Del 10bpexon 6 Moderate High - High
End-stage renal 
failure (39), renal 
transplant 
Mild - High
Death from 
complications of 
renal transplant 
surgery (39)
41 P250T missense Moderate Low
Severe mitral 
regurgitation (53) Low - Moderate Stroke (52) High -
43 R342Q  missense Moderate High
Severe mitral 
regurgitation (47), 
mitral valve repair 
(49), infective 
endocarditis *(57)
High - Moderate Stroke *(57) High -
47 N215S (missense) Moderate Medium
Implantable cardiac 
defibrillator for 
paroxysmal SVT 
(61)
High
Dialysis dependent 
renal failure (51), 
renal transplant (54)
Severe - High -
50 R342Q  missense Severe High
Dual chamber 
cardiac pacemaker 
(56)
High - Moderate - High -
51 R227X nonsense Moderate High
Cardiac bypass 
surgery (58) High - Moderate TIA (61), stroke (63) High -
Figure 1. Kaplan-Meier analyses of time in years post-ERT initiation to defined disease-
related endpoints of  low, medium (expect in composite) or high-risk FIPI groups (n=15) A. 
Composite (FIPI) endpoints (p=0.029). B. Cardiovascular endpoints (p=0.78). C. Neurological 
endpoints (p=0.22). D. Renal endpoints (p=0.36).  A breakdown of patient numbers in each 
group in given in Table 2.  
Table 2: The total number of patients in composite, cardiovascular, neurological and renal FIPI 
groups presented as per risk group with the number reaching a defined endpoint listed in 
brackets.
4. Discussion
This cohort of FD patients has received ERT for longer than any other, and, in terms of 
outcomes on therapy, only four patients had not reached any of our defined endpoints after 
up to 14 years of follow-up. Eleven patients experienced serious Fabry-related cardiac, renal, 
and/or neurological events, and three patients died as a result of Fabry disease and its 
complications. This is a small cohort with which to compare published natural history studies. 
The mean cumulative survival of a cohort of male Fabry patients reported around the start of 
the observation period of our study was 50 years (Macdermot et al 2001 ). A comparative 
statistic cannot be calculated in our cohort as 12/15 patients are alive however current 
survival is 52 years (range: 37-65 years).  
The FIPI score for time to the composite endpoint demonstrated a statistically significant 
difference between the high and low-risk groups. The high-risk group experienced more 
Fabry-related complications and did so earlier than patients in the lower-risk group.  
Therefore, calculation of this score may be beneficial for determining prognosis for patients 
starting ERT, and its use of readily available clinical parameters makes it easily accessible to 
physicians treating the disease. Although the cardiac, renal, and neurological scores showed 
no significant difference between groups, there was a non-significant trend towards poorer 
organ-specific outcomes in the higher risk cardiac and renal groups and therefore detailed 
clinical assessment prior to ERT is likely to be as informative as the subscores.  The 
neurological FIPI score did not seem to be able to distinguish risk for stroke which were all in 
low and medium risk groups with none in the high risk group. This may reflect are cardiological 
component to stroke in Fabry as the neurological subscore was not derived to include any 
cardiac parameters.
No single clinical factor was more able to predict the overall outcome. Analyses MSSI groups, 
urine and plasma Gb3 concentrations, and the presence or absence of neutralizing antibodies 
had no predictive value for significant disease-related clinical outcomes in this study.  This is 
in contrast to a previous study where baseline urine Gb3 excretion significantly predicted 
change from baseline estimated glomerular filtration rate in patients receiving agalsidase alfa 
for 12 months (Schiffmann et al 2013). Analysis by genotype was also not predictive for 
example the two patients with the N215S mutations had similar baseline leucocyte alpha 
galactosidase enzyme activities but fell into different FIPI subgroups and experienced distinct 
outcomes. 
FIPI risk 
severity
Composite FIPI
(endpoint)
Cardiovascular FIPI
(endpoint)
Neurological FIPI
(endpoint)
Renal FIPI
(endpoint)
Low 6 (2) 2 (1) 7 (1) 2 (0)
Medium n/a 6 (2) 6 (4) 3  (0)
High 9 (9) 7 (4) 2 (0) 10 (4)
As ERT was not available prior to the trial, many patients had advanced disease. It is possible 
that clinical outcomes may have been better if earlier initiation of ERT had been possible for 
these patients and indeed those patients progressing prior to ERT are more likely to perform 
poorly on ERT (Hopkin et al 2016)
The main strength of this study is the length of follow-up on ERT is greater than any previously 
published, and hence represents an excellent starting point to validate the FIPI score as a 
method of discriminating groups of patents with varying response to ERT. Limitations include 
the small patient cohort, which was heterogeneous in age, genotype and disease severity and 
that the patients may have experienced more clinical progression prior to therapy since it had 
not been previously available. To validate the use of the FIPI conclusively for prediction of 
prognosis on ERT, larger numbers of patients on long-term ERT would be required. 
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Supplementary table
Variable Score
Cardiac
 eGFR <60 ml/min/1.73 m2 1.5
 Hearing impairment* 1.0
 LVM index ≥50 g/m2.7 1.0
 Proteinuria (>300 mg/24 h) 0.5
 Presence of vertigo 0.5
 Presence of angiokeratomas or telangiectasias 2.0
 
Renal
 eGFR <60 ml/min/1.73 m2 2.0
Variable Score
 Gender—male 1.5
 Proteinuria (>300 mg/24 h) 1.5
 Presence of angiokeratomas or telangiectasias 2.0
 
Neurological
 Hearing impairment* 2.5
 eGFR <60 ml/min/1.73 m2 2.0
 Presence of vertigo 1.5
 Presence of anhidrosis/hypohidrosis 1.0
Composite
 eGFR <60 ml/min/1.73 m2 2.0
 Hearing impairment* 2.0
 Microalbuminuria 1.0
 LVM index ≥50 g/m2 1.0
 Presence of anhidrosis/hypohidrosis 1.0
 Total composite
 ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; LVM, left 
ventricular mass.
 ↵* Hearing impairment is average pure tune audiometric thresholds at 0.5, 1 and 2 
kHz in one or both ears > 25 dB ISO.
Supplementary table.  The variables contributing to the, cardiovascular, neurological, 
renal, and composite FIPI scores.
